Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Lymphoma 3Waldenstrom Macroglobulinemia 2Neoplasms 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 10fludarabine 7pomalidomide 5pembrolizumab 5Dexamethasone 5daratumumab 4obinutuzumab 3glofitamab 3fludarabine phosphate 3abemaciclib 3Rituximab 3Melphalan 3Immunotherapy, Adoptive 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2pirtobrutinib 2palbociclib 2cemiplimab 2blinatumomab 2Temozolomide 2Sirolimus 2Oxaliplatin 2Nivolumab 2Mesna 2Letrozole 2Injections 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × ibrutinib × 30 days × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡